Amarin Corporation Plc · NASDAQ:AMRN
Amarin — Q4 2025 Earnings Presentation
13 slides from Amarin's earnings presentation, Feb 25, 2026
Slide 1: Evidence-Based Therapy to Reduce Life-Threatening Cardiovascular Events
EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS Company Overview NASDAQ: AMRN FEBRUARY 2026
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and prici
Slide 3: A Message from our President & CEO
A Message from our President & CEO “We continue to take a strategic, disciplined approach to transforming our business and unlocking its significant untapped potential – all from a position of strength. We have maintained a leading U.S. market share for VASCEPA® and executed a fully-partnered intern
Slide 4: Who We Are: An Established Leader in Cardiovascular Therapeutics
Who We Are: An Established Leader in Cardiovascular Therapeutics • First and only FDA-approved oral therapy to reduce cardiovascular (CV) risk when added to recommended statin therapy. • 2018 groundbreaking clinical study1 proved that VASCEPA lowers the chance of a life-threatening CV event (such as
Slide 5: Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position
Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position; Poised for Long-Term Growth • Transformed international commercial strategy; fully partnered and covering close to 100 countries; emphasis on Europe (Intellectual Property protection through 2039). • Restru
Slide 6: Our Financials: Restructuring Initiatives Further Strengthening Amarin's Fundamentals
Our Financials: Restructuring Initiatives Further Strengthening Amarin’s Fundamentals While Positioning Us for Future Global Growth Key Takeaways: Operating Results: ($ in M) Q4 25 Q4 24 Change Q4 2025 net revenue of $49.2 M, and FY 2025 Net Revenue 49.2 62.3 (21)% revenue of $213.6 M. U.S. Product
Slide 7: Our U.S. Business: Implemented and Successfully Executing Refined Commercial Strategy
Our U.S. Business: Implemented and Successfully Executing Refined Commercial Strategy to Maintain Profitable Branded Business • Proven efficacy in CVRR has built a large and durable U.S. market presence. • Implemented refined commercial strategy focused on payer coverage post- loss of exclusivity, p
Slide 8: Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners
Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners CANADA EUROPE Commercialization efforts New exclusive license & supply progressing agreement CHINA CVRR approval secured; Focus on Private Pay Market SOUTH KOREA AND ASEAN South Korea and Singapore regu
Slide 9: Our International Business: A Pivotal Year for Europe; Recordati Partnership
Our International Business: A Pivotal Year for Europe; Recordati Partnership Key To Maximize VAZKEPA Opportunity in Europe • June 2025: exclusive, long-term license and supply agreement; 15- year initial term, auto renewal in 2039. • Recordati to commercialize VAZKEPA in 59 countries, primarily Euro
Slide 10: Our International Business: 2025 - A Year of Steady Progress
Our International Business: 2025 - A Year of Steady Progress; Seven Partners Actively Building Market Opportunities Across Multiple Continents 7 Ex-U.S. partnerships focused on maximizing patient access to VASCEPA/ Regulatory: VAZKEPA – many in early commercialization stages, poised for future growt
Slide 11: Improving Market Dynamics: Regulatory Label Changes and Amplified Disease Awareness
Improving Market Dynamics: Regulatory Label Changes and Amplified Disease Awareness of Elevated Triglycerides/FCS Positive for VASCEPA / VAZKEPA Fibrate Label Change Amplified Disease Awareness Innovation in the triglyceride space is advancing June 2025 - FDA updated the labelling requirements for a
Slide 12: 2026 Focus: Continued Execution & Driving Long-term Growth Opportunities
2026 Focus: Continued Execution & Driving Long-term Growth Opportunities A multi-pronged and multi-national approach: • Expand therapeutic reach across all partnered international markets. • Realize the full operational improvements from global restructuring initiatives. • Maintain IPE leadership in
Slide 13: Amarin Key Takeaways
Amarin Key Takeaways HEALTHY FINANCIALS UNTAPPED POTENTIAL PRODUCT POWER STRONG SCIENCE MEDICAL ENDORSEMENT Q4 ‘25 ~640M PEOPLE LIVING WITH CVD, >250K 3 500+ CASH FLOW POSITIVE MAKING IT THE LEADING CAUSE SUCCESSFUL PHASE 3 SCIENTIFIC PUBLICATIONS PRESCRIBERS (EARLIER THAN ANTICIPATED) OF DEATH WORL